Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in forty-three countries.
Rachel H. Giles(Dutch Cancer Society), Eric Jonasch(The University of Texas MD Anderson Cancer Center), Michael A.S. Jewett(Princess Margaret Cancer Centre), Robin Martinez(Patients First), Axel Bex(The Royal Free Hospital), James Larkin(Trinity College Dublin), Sara MacLennan(University of Aberdeen), Deb Maskens, Robert Bick(Kidney Foundation of Canada), Daniel Yick Chin Heng(University of Calgary), Malcolm Packer(Kidney Care UK)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k